Tipsheet
What matters at India’s listed companies
Concalls · Hospital & Healthcare · Mega cap

Max Healthcare delays Gurgaon hospital, cuts oncology revenue outlook

Management now expects the 500-bed Gurgaon facility by end-FY27, not H1. Oncology's share of revenue is seen stabilising at 21-22%, down from a prior 25-26%.

3 earlier stories on Max Healthcare Institute Ltd.
Mkt cap₹1.09 lakh cr
P/E75.80×
ROE11.47%
Debt / eq.0.27
Div yld0.18%
21-22% New expected stabilisation point for oncology revenue mix, down from 25-26%.

What's new

  • Gurgaon greenfield hospital commissioning delayed by ~6 months to end-FY27.
  • Oncology revenue mix outlook cut to 21-22% from 25-26% due to CGHS drug pricing.
  • Brownfield capacity additions of 20%+ remain on track across the network.

Why this matters

The Gurgaon delay is a modest pushback, but the oncology mix revision is structural. It ties directly to a regulatory change (CGHS pricing) that won't reverse, trimming a high-margin segment's contribution to the revenue base. This changes the margin trajectory for the hospital network.

What we're watching

  • Whether the ₹1,400 cr Lucknow project faces similar timeline slippage.
  • Margin impact as lower-margin non-oncology volume makes up the revenue mix.
  • Execution on the 20%+ brownfield capacity additions this fiscal.

The full read

Max Healthcare's conference call contained two downward revisions. The 500-bed Gurgaon greenfield hospital will now be commissioned by end-FY27, not H1 as previously guided, a six-month delay. More consequentially, management flagged a permanent shift in its oncology revenue mix. The segment will stabilise at 21-22% of revenue, down from a prior 25-26%, due to CGHS drug pricing changes. That's a structural hit to a high-margin business line. The remaining guidance was steady: brownfield additions of 20%+ are on track, and the ₹1,400 crore Lucknow greenfield is progressing on schedule. The oncology revision is the one to watch. CGHS pricing pressure doesn't abate, and it reshapes the revenue mix toward lower-margin general medicine.

Questions answered

Why is Max Healthcare's oncology revenue share falling?
Management cited changes to CGHS drug pricing. This regulatory adjustment is lowering the revenue contribution from oncology, which is now expected to stabilise at 21-22% of the mix, down from a prior 25-26% range.
How significant is the Gurgaon hospital delay?
The 500-bed greenfield hospital is now expected by end-FY27, a delay from the earlier H1 FY27 guidance. This pushes back the capacity addition by roughly six months within the current fiscal year.
Is the Lucknow hospital still on schedule?
Yes. The board-approved ₹1,400 crore greenfield hospital in Lucknow is progressing on schedule, management stated on the call.
What is the status of the company's brownfield expansion?
Brownfield capacity rollout remains on track, with management guiding for 20%+ additions across its network of existing facilities.
Mentioned: Gurgaon greenfield hospital · CGHS drug pricing · Lucknow ₹1,400 cr greenfield
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Max Healthcare Institute Ltd.

Hospitals
₹1.03 L cr
P/E 72.25×

Latest quarter · Mar 2026

Sales₹2,143 cr
Net profit₹342 cr
Op. margin+28.3%
EPS₹3.52

Strength & growth

Debt / equity0.27×
Current ratio0.88×
  1. 22 May 2026 · 12:22 PM IST Max Healthcare delays Gurgaon hospital, cuts oncology revenue outlook
  2. 46d ago Max Healthcare posts 10% revenue growth, maps ₹1,400 cr Lucknow greenfield hospital
  3. 46d ago Max Healthcare revenue up 16% in FY26, unveils ₹1,400 cr Lucknow hospital
  4. 46d ago Max Healthcare to build ₹1,400 cr hospital in Lucknow